Literature DB >> 19652620

Treatment options for uncomplicated diverticular disease of the colon.

Alba Rocco1, Debora Compare, Flora Caruso, Gerardo Nardone.   

Abstract

Patients affected by uncomplicated diverticular disease (DD) suffer from colicky, unexplained, recurrent, and short-lived but often debilitating abdominal pain and alteration in bowel habit. Although the goals of therapy, such as to improve symptoms and to prevent both recurrent attacks and complications, are clearly established, the standard approach remains still debated. We examined the current scientific evidence supporting the different treatment options for uncomplicated DD. An internet-based search strategy of the Medline and Science Citation Index was performed using the keywords: diverticulosis, DD, fiber, bran, diet, antibiotics, rifaximin, probiotics, prebiotics, bacteria, lactobacillus, bifidobacteria, 5-aminosalicylic acid, sulfasalazine, mesalazine, balsalazide in various combinations to select randomized trials published in the English language between January 1966 and March 2009. The use of fiber and nonabsorbable antibiotics is supported by the existence of randomized controlled studies. More recently, alternative treatments, such as probiotics and mesalazine have been proposed even if no definite data are available. Although the preliminary results seem to be promising, randomized, placebo-controlled studies are needed before new therapies can be recommended in the management of uncomplicated DD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19652620     DOI: 10.1097/MCG.0b013e3181b3ab2e

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  2 in total

1.  Medical treatment of colonic diverticular disease: are we sure the aim is right?

Authors:  Gabrio Bassotti; Vincenzo Villanacci
Journal:  Intern Emerg Med       Date:  2011-03-23       Impact factor: 3.397

2.  New strategies for the management of diverticular disease: insights for the clinician.

Authors:  Wen Boynton; Martin Floch
Journal:  Therap Adv Gastroenterol       Date:  2013-05       Impact factor: 4.409

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.